ibandronic acid has been researched along with Bone Loss, Osteoclastic in 135 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 35 (25.93) | 18.2507 |
| 2000's | 81 (60.00) | 29.6817 |
| 2010's | 17 (12.59) | 24.3611 |
| 2020's | 2 (1.48) | 2.80 |
| Authors | Studies |
|---|---|
| Cieslak, JA; Coates, RM; Fukura, S; Koohang, A; Lea, CR; Lee, HJ; Loftus, TC; Martin, MB; Matsumura, Y; Oldfield, E; Sagami, H; Sanders, JM; Sengupta, S; Szabo, CM | 1 |
| Martin, MB; Oldfield, E; Szabo, CM | 1 |
| Bachmann, R; Bisping, M; Born, AR; Cortesi, R; Glatt, M; Green, JR; Guiglia, G; Jaeggi, KA; Jeker, H; Klein, R; Müller, K; Ramseier, U; Schmid, J; Schreiber, G; Seltenmeyer, Y; Widler, L | 1 |
| Deleide, G; Fruttero, R; Gasco, A; Guenther, HL; Lazzarato, L; Lolli, ML; Rolando, B; Tron, GC | 1 |
| Hadjiargyrou, M | 1 |
| Aoki, K; Nakamura, M; Saito, N; Ueda, K; Yamamoto, Y; Yudasaka, M; Zhang, M | 1 |
| Shen, Y; Wang, HW; Wang, YX; Yang, DL; Zhang, W; Zhang, YZ; Zhen, ZJ | 1 |
| Aleksandrova, EN; Alekseeva, LI; Demin, NV; Sharapova, EP; Smirnov, AV; Taskina, EA; Zaitseva, EM | 1 |
| Criscitiello, C; Curigliano, G; De Laurentiis, M; De Placido, S; Esposito, A; Gelao, L; Goldhirsch, A; Santangelo, M; Viale, G | 1 |
| Geng, CJ; Liang, Q; Liang, R; Meng, FY; Wu, N; Yuan, BY; Zhong, JH; Zhu, M | 1 |
| Bauss, F; Endo, K; Hashimoto, J; Sakai, S; Shimizu, M; Shimonaka, Y; Sugimoto, M; Takeda, S; Yogo, K | 1 |
| Chung, YS; Kang, HC; Lee, T | 1 |
| Jäger, M; Krauspe, R; Rump, LC; Schmitz, M; Tillmann, FP | 1 |
| Fujita, N; Kobayashi, T; Matsumoto, M; Matsumoto, Y; Miyamoto, K; Miyamoto, T; Morita, M; Nakamura, M; Oike, T; Sato, Y; Takeda, S; Watanabe, R | 1 |
| Callaci, JJ; Himes, R; Wezeman, FH | 1 |
| Body, JJ | 2 |
| Binkley, N; Dasic, G; Kohles, JD; Santiago, N; Silverman, SL; Simonelli, C; Sunyecz, JA | 1 |
| Dimai, HP; Dobnig, H; Fahrleitner-Pammer, A; Hauge, E; Obermayer-Pietsch, BM; Pieber, TR; Pilz, S; Piswanger-Soelkner, JC; Portugaller, RH; Prenner, G; Tscheliessnigg, KH | 1 |
| Li, M; Liu, DG; Liu, JL; Meng, XW; Xia, WB; Xing, XP; Zhang, ZL | 1 |
| Dziegiel, MH; Henriksen, K; Karsdal, MA; Kocijancic, D; Leeming, DJ; Neutzsky-Wulff, AV; Sørensen, MG | 1 |
| Hatzopoulos, A; Heras, P; Heras, V; Karagiannis, S; Kritikos, K; Kritikos, N | 1 |
| Bauss, F; Caeiro, JR; Dapia, S; De La Piedra, C; Diaz-Curiel, M; Montero, M; Quiroga, I; Rubert, M | 1 |
| Jones, G; Winzenberg, T | 1 |
| Bargagli, G; Conca, R; Cozzolino, A; Fiaschi, AI; Francini, E; Francini, F; Gotti, G; Martellucci, I; Miano, ST; Migali, C; Pascucci, A; Petrioli, R | 1 |
| Dubourg, G; Giraudeau, B; Perrodeau, E; Ravaud, P; Rouanet, S; Roux, C | 1 |
| Åsberg, A; Bollerslev, J; Dolgos, S; Godang, K; Hartmann, A; Midtvedt, K; Olsen, IC; Pfeffer, P; Reisæter, AV; Sagedal, S; Smerud, KT; Ueland, T | 1 |
| Ignaczak, P; Jeka, S; Wegierska, M; Zalewska, J | 1 |
| Omid, N; Price, PA; Than, TN; Williamson, MK | 1 |
| Abendroth, K; Hein, G; Hommann, M; Kornberg, A; Lehmann, G; Patzer, N; Scheele, J; Seifert, S; Voigt, R | 1 |
| Bauss, F; Endele, R; Hothorn, LA; Lalla, S | 1 |
| Hu, MY; Wang, BC; Zhou, XQ | 1 |
| Frith, JC; Rogers, MJ | 1 |
| Bauss, F; Hannan, M; Müller, R; Recker, RR; Smith, SY | 1 |
| Berenson, JR | 1 |
| de la Fuente, J; Goldman, JM; Karkantaris, C; Meletis, J; Palermos, J; Rahemtulla, A; Terpos, E; Vaiopoulos, G; Viniou, N; Voskaridou, E; Yataganas, X | 1 |
| Bauss, F; Schimmer, RC | 1 |
| Bauss, F; Bloomfield, S; Fedarko, N; Hogan, HA; Rastogi, S; Ruff, CB; Ruiz, J; Schultheis, L; Shapiro, JR; Thierry-Palmer, M | 1 |
| Bergström, B; Pecherstorfer, M; Rizzoli, R; Steinhauer, EU; Wetterwald, M | 1 |
| Baumann, M; Christgau, S; Christiansen, C; Hoyle, N; Lehmann, HJ; Moelgaard, A; Mouritzen, U; Qvist, P; Tankó, LB; Warming, L; Wieczorek, L | 1 |
| Baumann, M; Christgau, S; Christiansen, C; Hoyle, N; Moelgaard, A; Qvist, P; Tankó, LB; Warming, L; Wieczorek, L | 1 |
| Burdeska, A; Christiansen, C; Czerwiński, E; Felsenberg, D; Hughes, C; Jonkanski, I; Tankó, LB | 1 |
| Dobrokhotov, IV; Durnova, GN; Il'ina-Kakueva, EI; Kaplanskiĭ, AS; Larina, IM; Morukov, BV | 1 |
| Nguyen, TM; Price, PA; Than, TN; Williamson, MK | 1 |
| Bjarnason, NH | 1 |
| Westermann, AM | 2 |
| Bell, R; Bergstrom, B; Body, JJ; Diel, IJ; Lazarev, A; Lichinitzer, M; Pecherstorfer, M; Tripathy, D | 1 |
| Kuwahara, T; Suzuki, M; Tanaka, Y; Yamada, T | 1 |
| Cundy, T; King, A; Wheadon, L | 1 |
| Chesnut, CH; Christiansen, C; Delmas, PD; Emkey, R; Gilbride, J; Recker, RR; Schimmer, RC; Skag, A; Stakkestad, JA | 1 |
| Rizzoli, R | 1 |
| Adami, S; Christiansen, C; Coutant, K; Delmas, PD; Felsenberg, D; Lorenc, RS; Mahoney, P; Robinson, J; Schimmer, RC | 1 |
| Chesnut, CH; Christiansen, C; Delmas, PD; Ettinger, M; Hoiseth, A; Mahoney, P; Recker, R; Schimmer, RC; Skag, A; Stakkestad, JA | 1 |
| Alexandersen, P; Bagger, YZ; Christiansen, C; Qin, G; Tankó, LB | 1 |
| Bauss, F; Russell, RG | 1 |
| Kurth, AH | 1 |
| Bauss, F; Hannan, M; Müller, R; Smith, SY | 1 |
| Hoskin, PJ | 1 |
| Pecherstorfer, M | 1 |
| Gieschke, R; Goggin, T; Jacqmin, P; Pillai, G; Schimmer, RC; Steimer, JL | 1 |
| Heidenreich, A; Ohlmann, CH | 1 |
| Gennari, L | 1 |
| Harvey, HA | 1 |
| Bauss, F; Bian, H; Garces, A; Jenkins, J; Kim, HK; Randall, TS | 1 |
| Hosking, DJ; Pande, I | 1 |
| Baylink, DJ; Chesnut, CH; Emkey, R; Ettinger, MP; Harris, ST; Miller, PD; Recker, RR; Schimmer, RC; Wasnich, RD; Watts, NB | 1 |
| Bauss, F; Brkovic, D; Jakse, G; Linke, J | 1 |
| Bauss, F; Endele, R; Loew, H | 1 |
| Lipton, A | 1 |
| Barrett, J; Bonvoisin, B; Dumont, E; Reginster, JY; Wilson, KM | 1 |
| Epstein, S; Zaidi, M | 1 |
| Rackoff, PJ; Sebba, A | 1 |
| Karperien, M; Löwik, C; Papapoulos, S; van Beek, E | 1 |
| Dorst, A; Faber, H; Ringe, JD | 1 |
| Fietkau, R; Gundlach, KK; Lenz, JH; Mueller, PC; Schmidt, W; Steiner-Krammer, B | 1 |
| Bals, G; Bergner, R; Henrich, D; Hoffmann, M; Lenz, T; Ullmann, M; Uppenkamp, M | 1 |
| Epstein, S | 1 |
| Russell, RG | 1 |
| Diel, IJ | 1 |
| Aspenberg, P; Kesteris, U | 1 |
| Price, PA; Roublick, AM; Williamson, MK | 1 |
| De Broe, M; Ketteler, M; Persy, V | 1 |
| Blair, JM; Brennan, K; Dunstan, CR; Modzelewski, JR; Seibel, MJ; Zheng, Y; Zhou, H | 1 |
| Papapoulos, SE; Schimmer, RC | 1 |
| Callaci, JJ; Himes, R; Juknelis, D; Wezeman, FH | 1 |
| Alva, D; Cesareo, R; Contini, S; De Rosa, B; Iozzino, M; Lauria, A; Mallardo, L; Napolitano, C; Orsini, A; Reda, G | 1 |
| McKeage, K; Plosker, GL | 1 |
| Babbitt, AM; Bone, HG; Lewiecki, EM; Ozturk, ZE; Piziak, VK | 1 |
| Kouloulias, V; Kouskouni, E; Mystakidou, K; Parpa, E; Stathopoulou, E; Vlahos, L | 1 |
| Clemens, MR; Ghielmini, M; Jaeger, P; Krahl, D; Manegold, C; Scharla, SH; Schöter, KH; Thiébaud, D; Wüster, C | 1 |
| Bauss, F; Friedler, RM; Malluche, HH; Monier-Faugere, MC | 1 |
| Collin, P; Fleisch, H; Guenther, HL; Martin, TJ; Sahni, M | 1 |
| Body, JJ; Clemens, MR; Degardin, M; Herrmann, Z; Huss, HJ; Manegold, C; Pecherstorfer, M; Steinhauer, EU; Thiébaud, D; Thürlimann, B; Tubiana-Hulin, M; van Eijkeren, M | 1 |
| Fleisch, H; Guenther, HL; Vitté, C | 1 |
| Antic, VN; Fleisch, H; Mühlbauer, RC | 1 |
| Fleisch, H | 1 |
| Burckhardt, P; Fioroni, P; Juillerat, L; Leuenberger, P; Ludwig, H; Markert, M; Pecherstorfer, M; Sauty, A; Thiebaud, D; Zimmer-Roth, I | 1 |
| Body, JJ; Dumon, JC; Oleffe, V | 1 |
| Chilton, KM; Coxon, FP; Lawry, J; Rogers, MJ; Russell, RG; Smith, MO; Suri, S | 1 |
| Christiansen, C; Clemmesen, B; Ravn, P; Riis, BJ | 1 |
| Body, JJ; Hagberg, H; Herrmann, Z; Huss, HJ; Lichinitser, MR; Ralston, SH; Rizzoll, R; Steinhauer, EU; Thiébaud, D; Thürlimann, B; Tubiana-Hulin, M; Walls, J | 1 |
| Amin, D; Bilder, GE; Cornell, SA; Perrone, MH | 1 |
| Schlosser, K; Scigalla, P | 1 |
| Bauss, F; De Clerck, YA; Dunstan, C; Mundy, GR; Sasaki, A; Williams, PJ; Yoneda, T | 1 |
| Body, JJ; Buck, S; Huss, HJ; Ludwig, H; Pecherstorfer, M; Schlosser, K | 1 |
| Ziegler, J | 1 |
| Duvos, C; Mayer, H; Scutt, A | 1 |
| Burckhardt, P | 1 |
| Burckhardt, P; Huss, H; Juttmann, JR; Kriegbaum, H; Mulder, H; Schöter, KH; Thiébaud, D | 1 |
| Coxon, FP; Graham, R; Hughes, DE; Luckman, SP; Rogers, MJ; Russell, G | 1 |
| Baumann, M; Christensen, JO; Clemmesen, B; Ravn, P | 1 |
| Alexandersen, P; Bjarnason, NH; Christgau, S; Christiansen, C; Fledelius, C; Herling, C; Qvist, P; Ravn, P; Rosenquist, C | 1 |
| Bartl, R; Body, JJ; Burckhardt, P; Delmas, PD; Diel, IJ; Fleisch, H; Kanis, JA; Kyle, RA; Mundy, GR; Paterson, AH; Rubens, RD | 1 |
| Balfour, JA; Dooley, M | 1 |
| Bauss, F; Boyce, BF; Dallas, MR; Dallas, SL; Garrett, IR; Mundy, GR; Oyajobi, BO; Radl, J | 1 |
| Cohen, L; Löwik, C; Papapoulos, S; Pieterman, E; van Beek, E | 1 |
| Löwik, C; Papapoulos, S; van beek, E; van der Pluijm, G | 1 |
| Dosch, E; Grauer, A; Heichel, S; Knaus, J; Ziegler, R | 1 |
| Black, C; Coleman, RE; Huss, H; Kanis, J; Purohit, OP; Quinn, KJ; Schlosser, K; Vinholes, JJ | 1 |
| Arnala, I; Bauss, F; Boskey, AL; Geng, Z; Malluche, HH; Monier-Faugere, MC; Paschalis, EP; Qi, Q | 1 |
| Alexandersen, P; Møllgaard, A; Ravn, P | 1 |
| Berenson, J; Hortobagyi, G; Lipton, A; Major, PP | 1 |
| Bauss, F; Hovy, L; Kim, SZ; Kurth, AH; Sedlmeyer, I | 1 |
| Bauss, F; Geng, Z; Malluche, HH; Monier-Faugere, MC | 1 |
| Fisher, JE; Reszka, AA; Rodan, GA | 1 |
| Faus, SA; Price, PA; Williamson, MK | 1 |
| Bagger, Y; Christiansen, C; Ise, J; Riis, BJ; von Stein, T | 1 |
| Boewer, C; Delmas, PD; Euller-Ziegler, L; Facon, T; Fiere, D; Fontana, A; Herrmann, Z; Hrubisko, M; Lichinitser, MR; Menssen, HD; Sakalová, A; Singer, CR; Thiel, E; Wetterwald, M | 1 |
| Christgau, S; Christiansen, C; Cloos, PA; Lehmann, HJ; Mouritzen, U | 1 |
| Bergner, R; Boerner, D; Dill, K; Uppenkamp, M | 1 |
| Bauss, F; Bonjour, JP; Caverzasio, J; Rizzoli, R | 1 |
| Bauss, F; Bosies, E; Fleisch, H; Janner, M; Mühlbauer, RC; Schenk, R; Strein, K | 1 |
29 review(s) available for ibandronic acid and Bone Loss, Osteoclastic
| Article | Year |
|---|---|
Effects of bisphosphonates on appendicular fracture repair in rodents.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Bone Resorption; Denosumab; Diphosphonates; Estrogens; Femoral Fractures; Fractures, Stress; Glucocorticoids; Ibandronic Acid; Mice; Rats; Rodentia | 2022 |
Crosstalk between bone niche and immune system: osteoimmunology signaling as a potential target for cancer treatment.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone and Bones; Bone Density Conservation Agents; Bone Diseases; Bone Neoplasms; Bone Remodeling; Bone Resorption; Clodronic Acid; Denosumab; Diphosphonates; Humans; Ibandronic Acid; Imidazoles; Immune System; Osteoclasts; Osteoprotegerin; Pamidronate; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Signal Transduction; Treatment Outcome; Zoledronic Acid | 2015 |
Ibandronate to treat skeletal-related events and bone pain in metastatic bone disease or multiple myeloma: a meta-analysis of randomised clinical trials.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Diphosphonates; Europe; Humans; Ibandronic Acid; Multiple Myeloma; Musculoskeletal Pain; Randomized Controlled Trials as Topic; Treatment Outcome | 2015 |
[Update on treatment of postmenopausal osteoporosis].
Topics: Bone Resorption; Calcium; Diphosphonates; Estrogen Replacement Therapy; Female; Fractures, Bone; Humans; Ibandronic Acid; Imidazoles; Meta-Analysis as Topic; Osteoporosis, Postmenopausal; Patient Compliance; Zoledronic Acid | 2008 |
Treatment of hypercalcemia of malignancy with bisphosphonates.
Topics: Bone Resorption; Clinical Trials as Topic; Clodronic Acid; Diphosphonates; Etidronic Acid; Humans; Hypercalcemia; Ibandronic Acid; Imidazoles; Neoplasms; Pamidronate; Zoledronic Acid | 2002 |
Effect of daily and intermittent use of ibandronate on bone mass and bone turnover in postmenopausal osteoporosis: a review of three phase II studies.
Topics: Administration, Oral; Biomarkers; Bone Density; Bone Resorption; Clinical Trials, Phase II as Topic; Diphosphonates; Drug Administration Schedule; Female; Humans; Ibandronic Acid; Injections, Intravenous; Osteoporosis, Postmenopausal; Time Factors | 2003 |
[Ibandronate].
Topics: Animals; Bone Density; Bone Resorption; Clinical Trials, Phase III as Topic; Diphosphonates; Humans; Ibandronic Acid; Osteoclasts; Osteoporosis, Postmenopausal; Patient Compliance; Randomized Controlled Trials as Topic; Spinal Fractures | 2004 |
Treatment of idiopathic hyperphosphatasia with intensive bisphosphonate therapy.
Topics: Alkaline Phosphatase; Audiometry, Pure-Tone; Biomarkers; Biopsy; Bone Conduction; Bone Density; Bone Resorption; Child; Collagen; Collagen Type I; Diphosphonates; Female; Humans; Ibandronic Acid; Infusions, Intravenous; Osteitis Deformans; Pamidronate; Pelvic Bones; Peptides; Radiography; Spine; Treatment Outcome | 2004 |
Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing.
Topics: Animals; Bone Density; Bone Resorption; Diphosphonates; Drug Administration Schedule; Humans; Ibandronic Acid; Models, Animal; Osteoporosis | 2004 |
Efficacy and safety of ibandronate in the treatment of neoplastic bone disease.
Topics: Bone Diseases; Bone Neoplasms; Bone Remodeling; Bone Resorption; Diphosphonates; Female; Humans; Ibandronic Acid; Male | 2004 |
A semimechanistic and mechanistic population PK-PD model for biomarker response to ibandronate, a new bisphosphonate for the treatment of osteoporosis.
Topics: Administration, Oral; Biomarkers; Bone Resorption; Clinical Trials as Topic; Collagen; Collagen Type I; Diphosphonates; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Humans; Ibandronic Acid; Infusions, Intravenous; Models, Biological; Osteoporosis, Postmenopausal; Peptides; Treatment Outcome | 2004 |
Ibandronate: its pharmacology and clinical efficacy in the management of tumor-induced hypercalcemia and metastatic bone disease.
Topics: Administration, Oral; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Diphosphonates; Humans; Hypercalcemia; Ibandronic Acid; Infusions, Intravenous; Neoplasms; Osteoporosis; Product Surveillance, Postmarketing; Risk Factors | 2004 |
Oral ibandronic acid.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Bone Neoplasms; Bone Resorption; Diphosphonates; Drugs, Investigational; Humans; Ibandronic Acid | 2005 |
Optimizing bisphosphonate therapy in patients with breast cancer on endocrine therapy.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Clinical Trials as Topic; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Letrozole; Nitriles; Pamidronate; Postmenopause; Triazoles; Zoledronic Acid | 2004 |
Oral antiresorptive therapy.
Topics: Administration, Oral; Alendronate; Anabolic Agents; Bone Resorption; Diphosphonates; Drug Therapy, Combination; Etidronic Acid; Fractures, Bone; Glucocorticoids; Humans; Ibandronic Acid; Osteoporosis; Raloxifene Hydrochloride; Risedronic Acid; Selective Estrogen Receptor Modulators; Teriparatide | 2005 |
New therapeutic agents for the treatment of bone diseases.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Diseases; Bone Diseases, Metabolic; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Diphosphonates; Humans; Ibandronic Acid; Imidazoles; Pamidronate; Randomized Controlled Trials as Topic; Zoledronic Acid | 2005 |
Biological properties and mechanism of action of ibandronate: application to the treatment of osteoporosis.
Topics: Bone and Bones; Bone Resorption; Diphosphonates; Drug Administration Schedule; Humans; Ibandronic Acid; Osteoporosis | 2005 |
Optimizing administration of bisphosphonates in women with postmenopausal osteoporosis.
Topics: Administration, Oral; Alendronate; Bone Resorption; Diphosphonates; Etidronic Acid; Female; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal; Risedronic Acid | 2005 |
Ibandronate treatment for osteoporosis: rationale, preclinical, and clinical development of extended dosing regimens.
Topics: Animals; Bone Density Conservation Agents; Bone Resorption; Clinical Trials as Topic; Diphosphonates; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Humans; Ibandronic Acid; Osteoporosis; Treatment Outcome | 2006 |
Ibandronate: pharmacology and preclinical studies.
Topics: Animals; Bone Density; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Disease Models, Animal; Drug Evaluation, Preclinical; Humans; Ibandronic Acid; Osteoporosis; Ovariectomy | 2006 |
Ibandronate: efficacy in the treatment of metastatic bone disease.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Clinical Trials as Topic; Diphosphonates; Humans; Ibandronic Acid | 2005 |
Changes in bone remodelling and antifracture efficacy of intermittent bisphosphonate therapy: implications from clinical studies with ibandronate.
Topics: Administration, Oral; Bone Density Conservation Agents; Bone Remodeling; Bone Resorption; Diphosphonates; Drug Administration Schedule; Female; Fractures, Bone; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal; Treatment Outcome | 2007 |
Evidence based medicine and effective interventions of pharmacological therapy for the prevention of osteoporotic fractures.
Topics: Alendronate; Bone Density Conservation Agents; Bone Resorption; Calcitonin; Clodronic Acid; Diphosphonates; Etidronic Acid; Evidence-Based Medicine; Female; Fractures, Bone; Humans; Ibandronic Acid; Organometallic Compounds; Osteoporosis, Postmenopausal; Risedronic Acid; Selective Estrogen Receptor Modulators; Teriparatide; Thiophenes; Vitamin D | 2007 |
Zoledronic acid: a pharmacoeconomic review of its use in the management of bone metastases.
Topics: Administration, Oral; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Cost-Benefit Analysis; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Lung Neoplasms; Male; Multiple Myeloma; Pamidronate; Prostatic Neoplasms; Quality-Adjusted Life Years; Zoledronic Acid | 2008 |
Tumor-induced hypercalcemia in a patient with extensive soft tissue sarcoma: effects of bisphosphonate therapy and surgery.
Topics: Adult; Bone Resorption; Chemotherapy, Adjuvant; Diphosphonates; Female; Humans; Hypercalcemia; Ibandronic Acid; Leg; Sarcoma, Synovial; Time Factors | 1996 |
Ibandronate in oncology.
Topics: Bone Density; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Calcium; Diphosphonates; Female; Humans; Hypercalcemia; Ibandronic Acid; Neoplasms; Osteoporosis, Postmenopausal; Randomized Controlled Trials as Topic | 1997 |
Current use of bisphosphonates in oncology. International Bone and Cancer Study Group.
Topics: Analgesics, Non-Narcotic; Bone and Bones; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Clodronic Acid; Diphosphonates; Humans; Hypercalcemia; Ibandronic Acid; Multiple Myeloma; Pain; Pamidronate | 1998 |
Ibandronate.
Topics: Animals; Bone Density; Bone Neoplasms; Bone Resorption; Diphosphonates; Female; Humans; Hypercalcemia; Ibandronic Acid; Male; Neoplasms; Osteitis Deformans; Osteoporosis, Postmenopausal | 1999 |
Oral bisphosphonates: A review of clinical use in patients with bone metastases.
Topics: Alendronate; Biological Availability; Bone Density; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Calcium; Clodronic Acid; Diphosphonates; Double-Blind Method; Etidronic Acid; Humans; Ibandronic Acid; Imidazoles; Male; Multiple Myeloma; Pamidronate; Prostatic Neoplasms; Pyridines; Randomized Controlled Trials as Topic; Risedronic Acid; Zoledronic Acid | 2000 |
41 trial(s) available for ibandronic acid and Bone Loss, Osteoclastic
| Article | Year |
|---|---|
Monthly ibandronate suppresses serum CTX-I within 3 days and maintains a monthly fluctuating pattern of suppression.
Topics: Bone Density Conservation Agents; Bone Remodeling; Bone Resorption; Collagen Type I; Diphosphonates; Double-Blind Method; Drug Administration Schedule; Female; Humans; Ibandronic Acid; Middle Aged; Osteoporosis, Postmenopausal; Peptides; Prospective Studies; Treatment Outcome | 2009 |
Ibandronate prevents bone loss and reduces vertebral fracture risk in male cardiac transplant patients: a randomized double-blind, placebo-controlled trial.
Topics: Acid Phosphatase; Adult; Antacids; Biomarkers; Bone Density Conservation Agents; Bone Resorption; Calcium Carbonate; Cholecalciferol; Collagen Type I; Diphosphonates; Double-Blind Method; Heart Transplantation; Humans; Ibandronic Acid; Isoenzymes; Lumbar Vertebrae; Male; Middle Aged; Radiography; Spinal Fractures; Tartrate-Resistant Acid Phosphatase; Time Factors; Transplantation, Homologous | 2009 |
Infusion of ibandronate once every 3 months effectively decreases bone resorption markers and increases bone mineral density in Chinese postmenopausal osteoporotic women: a 1-year study.
Topics: Aged; Alkaline Phosphatase; Biomarkers; Body Height; Bone Density; Bone Density Conservation Agents; Bone Resorption; China; Collagen Type I; Diphosphonates; Female; Femur; Femur Neck; Humans; Ibandronic Acid; Infusions, Intravenous; Lumbar Vertebrae; Middle Aged; Muscular Diseases; Osteoporosis, Postmenopausal; Pain; Peptides; Time Factors | 2010 |
A comparative study of intravenous ibandronate and pamindronate in patients with bone metastases from breast or lung cancer: effect on metastatic bone pain.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Diphosphonates; Female; Humans; Ibandronic Acid; Lung Neoplasms; Male; Middle Aged; Pain; Pamidronate; Quality of Life | 2011 |
Effects of intravenous zoledronic acid and oral ibandronate on early changes in markers of bone turnover in patients with bone metastases from non-small cell lung cancer.
Topics: Administration, Oral; Aged; Alkaline Phosphatase; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Neoplasms; Bone Remodeling; Bone Resorption; Carcinoma, Non-Small-Cell Lung; Collagen Type I; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Injections, Intravenous; Lung Neoplasms; Male; Middle Aged; Peptides; Treatment Outcome; Zoledronic Acid | 2011 |
Monitoring of bone turnover markers does not improve persistence with ibandronate treatment.
Topics: Biomarkers; Bone Density Conservation Agents; Bone Resorption; Collagen Type I; Diphosphonates; Drug Monitoring; Female; Humans; Ibandronic Acid; Male; Medication Adherence; Middle Aged; Osteoporosis, Postmenopausal; Prospective Studies | 2012 |
A 1-year randomized, double-blind, placebo-controlled study of intravenous ibandronate on bone loss following renal transplantation.
Topics: Administration, Intravenous; Bone Density; Bone Density Conservation Agents; Bone Resorption; Calcitriol; Calcium, Dietary; Diphosphonates; Double-Blind Method; Female; Humans; Ibandronic Acid; Kidney Transplantation; Male; Maximum Tolerated Dose; Middle Aged; Osteoporosis; Vitamins | 2012 |
Effect of transplantation on bone: osteoporosis after liver and multivisceral transplantation.
Topics: Bone Density; Bone Resorption; Calcium; Diphosphonates; Femur; Humans; Ibandronic Acid; Liver Transplantation; Lumbar Vertebrae; Osteoporosis; Postoperative Complications; Vitamin D | 2002 |
Pamidronate is superior to ibandronate in decreasing bone resorption, interleukin-6 and beta 2-microglobulin in multiple myeloma.
Topics: Acid Phosphatase; Aged; Antineoplastic Agents; beta 2-Microglobulin; Biomarkers; Bone Resorption; Collagen; Collagen Type I; Diphosphonates; Female; Humans; Ibandronic Acid; Interleukin-6; Isoenzymes; Male; Middle Aged; Multiple Myeloma; Osteogenesis; Pamidronate; Peptides; Tartrate-Resistant Acid Phosphatase | 2003 |
Efficacy and safety of ibandronate in the treatment of hypercalcemia of malignancy: a randomized multicentric comparison to pamidronate.
Topics: Administration, Oral; Aged; Anti-Inflammatory Agents; Bone Resorption; Diphosphonates; Female; Humans; Hypercalcemia; Ibandronic Acid; Male; Middle Aged; Neoplasms; Pamidronate; Treatment Outcome | 2003 |
Oral ibandronate: changes in markers of bone turnover during adequately dosed continuous and weekly therapy and during different suboptimally dosed treatment regimens.
Topics: Administration, Oral; Aged; Analysis of Variance; Biomarkers; Bone Regeneration; Bone Remodeling; Bone Resorption; Diphosphonates; Drug Administration Schedule; Female; Humans; Ibandronic Acid; Middle Aged; Osteogenesis; Osteoporosis, Postmenopausal | 2003 |
Dose dependent effects on bone resorption and formation of intermittently administered intravenous ibandronate.
Topics: Aged; Biomarkers; Bone Remodeling; Bone Resorption; Collagen; Collagen Type I; Diphosphonates; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Ibandronic Acid; Injections, Intravenous; Middle Aged; Osteocalcin; Peptides; Postmenopause | 2003 |
Oral weekly ibandronate prevents bone loss in postmenopausal women.
Topics: Administration, Oral; Alkaline Phosphatase; Analysis of Variance; Bone Density; Bone Resorption; Collagen Type I; Diphosphonates; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Ibandronic Acid; Middle Aged; Osteocalcin; Osteoporosis, Postmenopausal; Time Factors | 2003 |
Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Diphosphonates; Female; Fractures, Bone; Humans; Ibandronic Acid; Middle Aged; Morbidity; Placebos; Risk Factors | 2004 |
Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Biomarkers; Bone Density; Bone Resorption; Collagen; Collagen Type I; Creatinine; Diphosphonates; Double-Blind Method; Drug Administration Schedule; Female; Hip; Humans; Ibandronic Acid; Lumbar Vertebrae; Middle Aged; Osteocalcin; Peptides; Risk Factors; Spinal Fractures; Treatment Outcome | 2004 |
Efficacy and safety of ibandronate given by intravenous injection once every 3 months.
Topics: Aged; Bone Density; Bone Remodeling; Bone Resorption; Diphosphonates; Double-Blind Method; Female; Humans; Ibandronic Acid; Injections, Intravenous; Middle Aged; Osteoporosis; Placebos | 2004 |
Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis.
Topics: Aged; Bone Resorption; Diphosphonates; Double-Blind Method; Female; Fractures, Bone; Humans; Ibandronic Acid; Infusions, Intravenous; Middle Aged; Osteoporosis; Placebos; Postmenopause | 2004 |
Effective doses of ibandronate do not influence the 3-year progression of aortic calcification in elderly osteoporotic women.
Topics: Administration, Oral; Aged; Aged, 80 and over; Aortic Diseases; Bone Density; Bone Resorption; Calcinosis; Diphosphonates; Disease Progression; Double-Blind Method; Female; Humans; Ibandronic Acid; Injections, Intravenous; Long-Term Care; Middle Aged; Osteoporosis, Postmenopausal | 2005 |
Ibandronate produces significant, similar antifracture efficacy in North American and European women: new clinical findings from BONE.
Topics: Administration, Oral; Aged; Aged, 80 and over; Bone Density; Bone Resorption; Diphosphonates; Double-Blind Method; Drug Administration Schedule; Europe; Female; Humans; Ibandronic Acid; Middle Aged; North America; Osteoporosis; Postmenopause; Spinal Fractures; White People | 2005 |
Monthly oral ibandronate is well tolerated and efficacious in postmenopausal women: results from the monthly oral pilot study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Area Under Curve; Bone Remodeling; Bone Resorption; Collagen; Collagen Type I; Diphosphonates; Double-Blind Method; Drug Administration Schedule; Feasibility Studies; Female; Gastrointestinal Diseases; Humans; Ibandronic Acid; Middle Aged; Osteoporosis, Postmenopausal; Peptides | 2005 |
High bone-binding capacity of ibandronate in hemodialysis patients.
Topics: Adult; Aged; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Humans; Hyperparathyroidism, Secondary; Ibandronic Acid; Kidney Failure, Chronic; Middle Aged; Renal Dialysis; Treatment Outcome | 2005 |
Rinsing morcellised bone grafts with bisphosphonate solution prevents their resorption. A prospective randomised double-blinded study.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Bone Density; Bone Density Conservation Agents; Bone Resorption; Bone Transplantation; Diphosphonates; Double-Blind Method; Female; Femur; Humans; Ibandronic Acid; Male; Middle Aged; Prospective Studies; Reoperation; Solutions; Therapeutic Irrigation; Treatment Outcome | 2006 |
Adherence to and gastrointestinal tolerability of monthly oral or quarterly intravenous ibandronate therapy in women with previous intolerance to oral bisphosphonates: a 12-month, open-label, prospective evaluation.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Tolerance; Female; Follow-Up Studies; Gastrointestinal Diseases; Gastrointestinal Tract; Humans; Ibandronic Acid; Injections, Intravenous; Middle Aged; Osteoporosis; Prospective Studies; Time Factors; Treatment Outcome | 2008 |
Oral versus intravenous ibandronic acid: a comparison of treatment options for metastatic bone disease.
Topics: Administration, Oral; Aged; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Diphosphonates; Female; Humans; Ibandronic Acid; Infusions, Intravenous; Male; Neoplasms; Prognosis; Prospective Studies; Quality of Life | 2008 |
Methylpentylaminopropylidenebisphosphonate (BM 21.0955): a new potent and safe bisphosphonate for the treatment of cancer-associated hypercalcemia.
Topics: Aged; Bone Resorption; Calcium; Diphosphonates; Female; Humans; Hypercalcemia; Ibandronic Acid; Injections, Intravenous; Male; Middle Aged; Neoplasms | 1993 |
Randomized phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy.
Topics: Adult; Aged; Aged, 80 and over; Bone Resorption; Calcium; Diphosphonates; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fever; Humans; Hypercalcemia; Ibandronic Acid; Male; Middle Aged; Nausea; Neoplasms; Recurrence; Regression Analysis; Thrombocytopenia; Treatment Outcome | 1996 |
Interleukin-6 and tumor necrosis factor alpha levels after bisphosphonates treatment in vitro and in patients with malignancy.
Topics: Aged; Aged, 80 and over; Bone Resorption; Clodronic Acid; Diphosphonates; Female; Follow-Up Studies; Humans; Ibandronic Acid; Interleukin-1; Interleukin-6; Male; Middle Aged; Neoplasms; Pamidronate; Tumor Necrosis Factor-alpha | 1996 |
The effect on bone mass and bone markers of different doses of ibandronate: a new bisphosphonate for prevention and treatment of postmenopausal osteoporosis: a 1-year, randomized, double-blind, placebo-controlled dose-finding study.
Topics: Absorptiometry, Photon; Administration, Oral; Aged; Analysis of Variance; Biomarkers; Body Height; Body Weight; Bone Density; Bone Resorption; Calcium, Dietary; Collagen; Diphosphonates; Dose-Response Relationship, Drug; Double-Blind Method; Female; Femur; Forearm; Humans; Ibandronic Acid; Middle Aged; Osteoporosis, Postmenopausal; Treatment Outcome | 1996 |
Dose-response study of ibandronate in the treatment of cancer-associated hypercalcaemia.
Topics: Bone Resorption; Diphosphonates; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Hypercalcemia; Ibandronic Acid; Infusions, Intravenous; Male; Middle Aged | 1997 |
Biochemical markers as surrogates in clinical trials in patients with metastatic bone disease and osteoporosis.
Topics: Absorptiometry, Photon; Administration, Oral; Adult; Alkaline Phosphatase; Amino Acids; Biomarkers; Bone and Bones; Bone Resorption; Calcitriol; Creatinine; Diphosphonates; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Ibandronic Acid; Injections, Intravenous; Middle Aged; Osteocalcin; Osteoporosis, Postmenopausal; Parathyroid Hormone; Placebos; Procollagen | 1997 |
Administration of the bisphosphonate ibandronate (BM 21.0955) by intravenous bolus injection.
Topics: Aged; Aged, 80 and over; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Diphosphonates; Female; Humans; Ibandronic Acid; Injections, Intravenous; Middle Aged | 1996 |
Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis.
Topics: Absorptiometry, Photon; Bone Density; Bone Resorption; Diphosphonates; Double-Blind Method; Female; Humans; Ibandronic Acid; Injections, Intravenous; Osteoporosis, Postmenopausal | 1997 |
Changes in biochemical markers and bone mass after withdrawal of ibandronate treatment: prediction of bone mass changes during treatment.
Topics: Aged; Alkaline Phosphatase; Biomarkers; Bone Density; Bone Diseases, Metabolic; Bone Resorption; Collagen; Collagen Type I; Diphosphonates; Dose-Response Relationship, Drug; Double-Blind Method; Female; Femur; Follow-Up Studies; Forearm; Humans; Ibandronic Acid; Middle Aged; Osteocalcin; Peptides; Spine | 1998 |
Clinical evaluation of the Serum CrossLaps One Step ELISA, a new assay measuring the serum concentration of bone-derived degradation products of type I collagen C-telopeptides.
Topics: Aged; Biomarkers; Bone Density; Bone Resorption; Collagen; Collagen Type I; Diphosphonates; Enzyme-Linked Immunosorbent Assay; Estrogen Replacement Therapy; Female; Humans; Ibandronic Acid; Middle Aged; Norpregnenes; Osteoporosis, Postmenopausal; Peptides; Sensitivity and Specificity | 1998 |
Ibandronate treatment in Paget's disease of bone.
Topics: Alkaline Phosphatase; Bone Resorption; Diphosphonates; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Ibandronic Acid; Infusions, Intravenous; Injections, Intravenous; Osteitis Deformans; Prospective Studies; Retreatment; Treatment Outcome | 1999 |
Double-blind, randomised, placebo-controlled, dose-finding study of oral ibandronate in patients with metastatic bone disease.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Analysis of Variance; Area Under Curve; Biomarkers; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Calcium; Diphosphonates; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Ibandronic Acid; Male; Middle Aged; Multiple Myeloma; Prognosis; Prospective Studies; Prostatic Neoplasms; Survival Rate; Treatment Outcome | 1999 |
Bone densitometry: a new, highly responsive region of interest in the distal forearm to monitor the effect of osteoporosis treatment.
Topics: Absorptiometry, Photon; Adult; Aged; Alendronate; Analysis of Variance; Bone Resorption; Diphosphonates; Dose-Response Relationship, Drug; Double-Blind Method; Estrogen Replacement Therapy; Female; Humans; Ibandronic Acid; Image Processing, Computer-Assisted; Linear Models; Male; Middle Aged; Osteoporosis, Postmenopausal; Radius; Sensitivity and Specificity; Ulna | 1999 |
Ibandronate: a comparison of oral daily dosing versus intermittent dosing in postmenopausal osteoporosis.
Topics: Administration, Oral; Aged; Biomarkers; Bone Density; Bone Resorption; Consumer Product Safety; Cross-Over Studies; Diphosphonates; Drug Administration Schedule; Drug Tolerance; Female; Hip; Humans; Ibandronic Acid; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal | 2001 |
Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma.
Topics: Bone Resorption; Chi-Square Distribution; Diphosphonates; Double-Blind Method; Female; Fractures, Bone; Humans; Hypercalcemia; Ibandronic Acid; Injections, Intravenous; Male; Middle Aged; Multiple Myeloma; Pain; Spinal Cord Compression; Survival Analysis; Treatment Outcome | 2002 |
Effect of bisphosphonates on cartilage turnover assessed with a newly developed assay for collagen type II degradation products.
Topics: Alendronate; Analysis of Variance; Bone Resorption; Cartilage; Collagen Type I; Collagen Type II; Diphosphonates; Double-Blind Method; Enzyme-Linked Immunosorbent Assay; Female; Humans; Ibandronic Acid; Middle Aged; Osteoporosis | 2002 |
Elimination of intravenously administered ibandronate in patients on haemodialysis: a monocentre open study.
Topics: Adult; Aged; Alanine Transaminase; Aspartate Aminotransferases; Blood Proteins; Bone Resorption; Diphosphonates; Female; Humans; Ibandronic Acid; Male; Metabolic Clearance Rate; Middle Aged; Renal Dialysis; Sex Characteristics | 2002 |
65 other study(ies) available for ibandronic acid and Bone Loss, Osteoclastic
| Article | Year |
|---|---|
Inhibition of geranylgeranyl diphosphate synthase by bisphosphonates and diphosphates: a potential route to new bone antiresorption and antiparasitic agents.
Topics: Alkyl and Aryl Transferases; Antiparasitic Agents; Bone Resorption; Diphosphonates; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Models, Molecular; Organophosphates; Quantitative Structure-Activity Relationship; Recombinant Proteins | 2002 |
An investigation of bone resorption and Dictyostelium discoideum growth inhibition by bisphosphonate drugs.
Topics: Alkyl and Aryl Transferases; Animals; Bone Resorption; Crystallography, X-Ray; Dictyostelium; Diphosphonates; Enzyme Inhibitors; Geranyltranstransferase; Humans; Inhibitory Concentration 50; Models, Molecular; Quantitative Structure-Activity Relationship; Rats | 2002 |
Highly potent geminal bisphosphonates. From pamidronate disodium (Aredia) to zoledronic acid (Zometa).
Topics: Animals; Bone Resorption; Calcitriol; Diphosphonates; Hypercalcemia; Imidazoles; In Vitro Techniques; Kidney; Mice; Pamidronate; Parathyroidectomy; Rats; Skull; Structure-Activity Relationship; Thyroidectomy; Zoledronic Acid | 2002 |
Synthesis of NO-donor bisphosphonates and their in-vitro action on bone resorption.
Topics: Animals; Bone Resorption; Carrier Proteins; Cell Differentiation; Cell Line; Diphosphonates; Durapatite; Male; Membrane Glycoproteins; Mice; NF-kappa B; Nitric Oxide Donors; Osteoclasts; Radiopharmaceuticals; RANK Ligand; Rats; Receptor Activator of Nuclear Factor-kappa B; Sodium Pertechnetate Tc 99m; Stem Cells; Structure-Activity Relationship; Tissue Distribution | 2005 |
Bisphosphonate type-dependent cell viability suppressive effects of carbon nanohorn-calcium phosphate-bisphosphonate nanocomposites.
Topics: Animals; Bone Neoplasms; Bone Resorption; Calcium Phosphates; Carbon; Cell Survival; Diphosphonates; Drug Carriers; Ibandronic Acid; Mice; Nanocomposites; Osteoclasts; Pamidronate; Reactive Oxygen Species; Zoledronic Acid | 2022 |
In vitro osteoclast-suppressing effect of sodium ibandronate.
Topics: Animals; Bone Resorption; Cell Movement; Cells, Cultured; Diphosphonates; Ibandronic Acid; Mice; Osteoclasts | 2013 |
[Evaluation of the efficacy and tolerance of ibandronic acid in patients with osteoarthrosis in the knee joints concurrent with osteoporosis: a pilot study].
Topics: Aged; Bone Density Conservation Agents; Bone Resorption; Cartilage; Diphosphonates; Disability Evaluation; Female; Humans; Ibandronic Acid; Locomotion; Middle Aged; Osteoarthritis, Knee; Osteoporosis, Postmenopausal; Pain; Pain Measurement; Pilot Projects; Severity of Illness Index | 2013 |
Treatment with the combination of ibandronate plus eldecalcitol has a synergistic effect on inhibition of bone resorption without suppressing bone formation in ovariectomized rats.
Topics: Animals; Biomechanical Phenomena; Body Weight; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Resorption; Calcium; Diphosphonates; Dose-Response Relationship, Drug; Drug Synergism; Female; Femur; Ibandronic Acid; Lumbar Vertebrae; Osteogenesis; Ovariectomy; Phosphorus; Rats; Rats, Wistar; Stress, Mechanical; Vitamin D | 2015 |
Comparative Effects of Ibandronate and Paclitaxel on Immunocompetent Bone Metastasis Model.
Topics: Amino Acids; Animals; Biomechanical Phenomena; Bone Density; Bone Neoplasms; Bone Resorption; Diphosphonates; Ibandronic Acid; Immunocompetence; Male; Neoplasm Metastasis; Osteolysis; Paclitaxel; Rats; Rats, Sprague-Dawley | 2015 |
Ibandronate in stable renal transplant recipients with low bone mineral density on long-term follow-up.
Topics: Absorptiometry, Photon; Adult; Bone Density; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Ibandronic Acid; Kidney Transplantation; Lumbar Vertebrae; Male; Osteoporosis; Retrospective Studies; Time Factors; Transplant Recipients; Treatment Outcome | 2016 |
Ibandronate concomitantly blocks immobilization-induced bone and muscle atrophy.
Topics: Animals; Bone Density Conservation Agents; Bone Resorption; Cell Line; Diphosphonates; Dose-Response Relationship, Drug; Female; Ibandronic Acid; Immobilization; Mice; Mice, Inbred C57BL; Muscular Atrophy; Organ Size; Proteasome Endopeptidase Complex; Treatment Outcome; Ubiquitination | 2016 |
Identification of novel bone-specific molecular targets of binge alcohol and ibandronate by transcriptome analysis.
Topics: Alcohol-Related Disorders; Animals; Bone Density; Bone Density Conservation Agents; Bone Resorption; Compressive Strength; Diphosphonates; Gene Expression Profiling; Gene Expression Regulation; Ibandronic Acid; Lumbar Vertebrae; Male; Oligonucleotide Array Sequence Analysis; Rats; Reverse Transcriptase Polymerase Chain Reaction | 2008 |
Alterations in osteoclast function and phenotype induced by different inhibitors of bone resorption--implications for osteoclast quality.
Topics: Animals; Bone Density Conservation Agents; Bone Resorption; Cattle; Cell Culture Techniques; Cell Differentiation; Cells, Cultured; Diphosphonates; Enzyme Inhibitors; Humans; Ibandronic Acid; Leucine; Macrolides; Macrophage Colony-Stimulating Factor; Monocytes; Osteoclasts; Phenotype; Protease Inhibitors; RANK Ligand | 2010 |
Daily or monthly ibandronate prevents or restores deteriorations of bone mass, architecture, biomechanical properties and markers of bone turnover in androgen-deficient aged rats.
Topics: Acid Phosphatase; Androgens; Animals; Biomechanical Phenomena; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Femur; Ibandronic Acid; Isoenzymes; Male; Orchiectomy; Osteocalcin; Peptide Fragments; Procollagen; Rats; Tartrate-Resistant Acid Phosphatase | 2011 |
When do bisphosphonates make the most sense?
Topics: Bone Density Conservation Agents; Bone Resorption; Clinical Trials as Topic; Diphosphonates; Dose-Response Relationship, Drug; Drug Therapy, Combination; Etidronic Acid; Female; Fractures, Bone; Humans; Ibandronic Acid; Middle Aged; Osteoporosis, Postmenopausal; Risedronic Acid; United States; Women's Health | 2011 |
[Paget's disease: case report].
Topics: Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Diagnosis, Differential; Diphosphonates; Female; Humans; Ibandronic Acid; Male; Middle Aged; Osteitis Deformans | 2011 |
The amino bisphosphonate ibandronate prevents calciphylaxis in the rat at doses that inhibit bone resorption.
Topics: Animals; Anthraquinones; Arteries; Bone Resorption; Calcinosis; Calcium; Chlorides; Diphosphonates; Drug Therapy, Combination; Ferric Compounds; Ibandronic Acid; Injections, Subcutaneous; Male; Phosphates; Rats; Rats, Sprague-Dawley; Skin; Staining and Labeling; Vitamin D | 2002 |
Effects of treatment with ibandronate on bone mass, architecture, biomechanical properties, and bone concentration of ibandronate in ovariectomized aged rats.
Topics: Absorptiometry, Photon; Aging; Animals; Bone and Bones; Bone Density; Bone Resorption; Diphosphonates; Dose-Response Relationship, Drug; Female; Femur; Ibandronic Acid; Injections, Subcutaneous; Lumbar Vertebrae; Ovariectomy; Rats; Rats, Wistar; Tibia; Time Factors | 2002 |
[Determination of ibandronate by high performance ion exchange chromatography].
Topics: Bone Resorption; Chromatography, Ion Exchange; Diphosphonates; Humans; Hydrogen-Ion Concentration; Ibandronic Acid; Reproducibility of Results | 2000 |
Antagonistic effects of different classes of bisphosphonates in osteoclasts and macrophages in vitro.
Topics: Adenosine Triphosphate; Alendronate; Animals; Apoptosis; Blotting, Western; Bone Resorption; Cell Line; Cell Membrane; Cell Nucleus; Cells, Cultured; Clodronic Acid; Diphosphonates; Dose-Response Relationship, Drug; Ibandronic Acid; Macrophages; Mice; Microscopy, Fluorescence; Osteoclasts; Pinocytosis; Rabbits; Time Factors | 2003 |
Intermittent intravenous administration of the bisphosphonate ibandronate prevents bone loss and maintains bone strength and quality in ovariectomized cynomolgus monkeys.
Topics: Animals; Bone Density; Bone Resorption; Diphosphonates; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Evaluation, Preclinical; Female; Ibandronic Acid; Injections, Intravenous; Macaca fascicularis; Ovariectomy | 2003 |
Disuse bone loss in hindquarter suspended rats: partial weightbearing, exercise and ibandronate treatment as countermeasures.
Topics: Animals; Bone Resorption; Collagen; Diphosphonates; Female; Hindlimb Suspension; Housing, Animal; Humerus; Ibandronic Acid; Physical Conditioning, Animal; Rats; Rats, Sprague-Dawley; Stress, Mechanical; Weight-Bearing; Weightlessness Countermeasures; Weightlessness Simulation | 2000 |
[Effects of ibandronate on the osteopenia process in tail-suspended rats].
Topics: Adrenal Glands; Animals; Bone Diseases, Metabolic; Bone Remodeling; Bone Resorption; Data Interpretation, Statistical; Diphosphonates; Hindlimb Suspension; Ibandronic Acid; Male; Rats; Thymus Gland; Tibia; Time Factors; Weightlessness | 2003 |
Serum levels of the fetuin-mineral complex correlate with artery calcification in the rat.
Topics: alpha-Fetoproteins; Animals; Aorta, Abdominal; Aortic Diseases; Bone Resorption; Calcinosis; Diphosphonates; Glycoproteins; Ibandronic Acid; Male; Minerals; Osteoprotegerin; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; Vitamin D | 2004 |
Bisphosphonates in children with bone diseases.
Topics: Bone Density; Bone Resorption; Child; Diphosphonates; Drug Administration Schedule; Humans; Ibandronic Acid; Male; Osteopetrosis; Pamidronate | 2003 |
Is ibandronate effective in multiple myeloma?
Topics: Bone Resorption; Diphosphonates; Humans; Ibandronic Acid; Multiple Myeloma; Randomized Controlled Trials as Topic | 2003 |
Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases.
Topics: Bone Neoplasms; Bone Resorption; Breast Neoplasms; Diphosphonates; Female; Humans; Ibandronic Acid; Incidence; Infusions, Intravenous | 2004 |
Bisphosphonates and reduction of skeletal events in patients with bone metastatic breast cancer.
Topics: Administration, Oral; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Clinical Trials as Topic; Diphosphonates; Dose-Response Relationship, Drug; Humans; Ibandronic Acid; Infusions, Intravenous | 2004 |
[Oral and parenteral forms of aminobisphosphonate].
Topics: Administration, Oral; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Colorectal Neoplasms; Diphosphonates; Humans; Ibandronic Acid; Infusions, Intravenous; Osteolysis; Spinal Neoplasms | 2004 |
[Bone metastases in breast carcinoma. Bisphosphonate protects from complications].
Topics: Administration, Oral; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Clinical Trials as Topic; Diphosphonates; Female; Humans; Hypercalcemia; Ibandronic Acid; Time Factors | 2004 |
Intermittent ibandronate preserves bone quality and bone strength in the lumbar spine after 16 months of treatment in the ovariectomized cynomolgus monkey.
Topics: Animals; Bone and Bones; Bone Density; Bone Remodeling; Bone Resorption; Densitometry; Diphosphonates; DNA; Dose-Response Relationship, Drug; Female; Ibandronic Acid; Linear Models; Lumbar Vertebrae; Lumbosacral Region; Macaca fascicularis; Osteoporosis; Ovariectomy; Ovary; Spine; Tensile Strength; Time Factors; Tomography, X-Ray Computed | 2004 |
The RIB trial.
Topics: Biomarkers; Bone Neoplasms; Bone Resorption; Clinical Trials as Topic; Diphosphonates; Humans; Ibandronic Acid; Pain | 2004 |
Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomized, double-blind, placebo-controlled trial.
Topics: Administration, Oral; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Diphosphonates; Ethics, Medical; Female; Humans; Ibandronic Acid; Placebos; Randomized Controlled Trials as Topic | 2005 |
Ibandronate for prevention of femoral head deformity after ischemic necrosis of the capital femoral epiphysis in immature pigs.
Topics: Animals; Bone Resorption; Diphosphonates; Epiphyses; Femur Head; Femur Head Necrosis; Ibandronic Acid; Infarction; Ischemia; Male; Osteolysis; Radiography; Swine | 2005 |
Changes in bone structure after augmentation cystoplasty in chronic uraemic rats.
Topics: Animals; Bone Density; Bone Resorption; Chronic Disease; Diphosphonates; Female; Ibandronic Acid; Rats; Rats, Sprague-Dawley; Renal Insufficiency; Uremia; Urinary Diversion | 2005 |
Analytical methods for the quantification of ibandronate in body fluids and bone.
Topics: Animals; Body Fluids; Bone Resorption; Diphosphonates; Enzyme-Linked Immunosorbent Assay; Gas Chromatography-Mass Spectrometry; Ibandronic Acid; Rats; Reference Standards | 2005 |
Independent pathways in the modulation of osteoclastic resorption by intermediates of the mevalonate biosynthetic pathway: the role of the retinoic acid receptor.
Topics: Animals; Bone and Bones; Bone Density Conservation Agents; Bone Resorption; Calcium; Diphosphonates; Diterpenes; Dose-Response Relationship, Drug; Drug Synergism; Female; Ibandronic Acid; Mevalonic Acid; Mice; Osteoclasts; Polyisoprenyl Phosphates; Pregnancy; Protein Prenylation; Receptors, Retinoic Acid | 2006 |
Effective and rapid treatment of painful localized transient osteoporosis (bone marrow edema) with intravenous ibandronate.
Topics: Adult; Bone Density; Bone Density Conservation Agents; Bone Marrow; Bone Resorption; Calcium, Dietary; Dietary Supplements; Diphosphonates; Edema; Female; Humans; Ibandronic Acid; Injections, Intravenous; Lumbar Vertebrae; Male; Middle Aged; Osteoporosis; Pain; Pain Measurement; Quality of Life; Syndrome; Treatment Outcome; Vitamin D | 2005 |
Does avascular necrosis of the jaws in cancer patients only occur following treatment with bisphosphonates?
Topics: Adult; Aged; Bone Density Conservation Agents; Bone Resorption; Breast Neoplasms; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Mandibular Diseases; Maxillary Diseases; Multiple Myeloma; Osteomyelitis; Osteonecrosis; Zoledronic Acid | 2005 |
Artery calcification in uremic rats is increased by a low protein diet and prevented by treatment with ibandronate.
Topics: alpha-Fetoproteins; Animals; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Resorption; Calcinosis; Calcium-Binding Proteins; Diet, Protein-Restricted; Dietary Proteins; Diphosphonates; Extracellular Matrix Proteins; Ibandronic Acid; Kidney; Male; Matrix Gla Protein; Osteocalcin; Rats; Rats, Sprague-Dawley; Renal Artery; Uremia; Vascular Diseases | 2006 |
Bisphosphonates prevent experimental vascular calcification: Treat the bone to cure the vessels?
Topics: Animals; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Resorption; Calcinosis; Diphosphonates; Ibandronic Acid; Kidney; Kidney Failure, Chronic; Mice; Rats; Vascular Diseases | 2006 |
Inhibition of bone resorption, rather than direct cytotoxicity, mediates the anti-tumour actions of ibandronate and osteoprotegerin in a murine model of breast cancer bone metastasis.
Topics: Animals; Apoptosis; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Diphosphonates; Drug Therapy, Combination; Female; Ibandronic Acid; Mice; Mice, Inbred BALB C; Mice, Nude; Osteoprotegerin; Tibia; Xenograft Model Antitumor Assays | 2007 |
Vitamin D and ibandronate prevent cancellous bone loss associated with binge alcohol treatment in male rats.
Topics: Alcohols; Animals; Bone Density; Bone Resorption; Calcium; Collagen Type I; Diphosphonates; Ibandronic Acid; Male; Rats; Rats, Sprague-Dawley; Spine; Stress, Mechanical; Vitamin D | 2007 |
A new bisphosphonate, BM 21.0955, prevents bone loss associated with cessation of ovarian function in experimental dogs.
Topics: Animals; Bone and Bones; Bone Resorption; Calcitriol; Diphosphonates; Dogs; Female; Ibandronic Acid; Models, Biological; Osteoporosis; Ovariectomy; Parathyroid Hormone | 1993 |
Bisphosphonates act on rat bone resorption through the mediation of osteoblasts.
Topics: Alendronate; Animals; Animals, Newborn; Bone Resorption; Cell Line; Cells, Cultured; Clodronic Acid; Culture Media, Conditioned; Diphosphonates; Dose-Response Relationship, Drug; Etidronic Acid; Ibandronic Acid; Kinetics; Osteoblasts; Pamidronate; Parathyroid Hormone; Rats; Rats, Wistar; Time Factors | 1993 |
Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast-mediated resorption.
Topics: Acid Phosphatase; Alendronate; Animals; Bone Resorption; Cell Line; Culture Media, Conditioned; Diphosphonates; Endopeptidases; Hot Temperature; Ibandronic Acid; Isoenzymes; Kinetics; Molecular Weight; Osteoblasts; Osteoclasts; Rats; Rats, Wistar; Tartrate-Resistant Acid Phosphatase | 1996 |
Effect of bisphosphonates on the increase in bone resorption induced by a low calcium diet.
Topics: Alendronate; Animals; Bone Resorption; Calcium; Calcium, Dietary; Clodronic Acid; Diphosphonates; Disease Models, Animal; Homeostasis; Ibandronic Acid; Male; Rats; Rats, Wistar; Tetracycline | 1996 |
The bisphosphonate ibandronate, given daily as well as discontinuously, decreases bone resorption and increases calcium retention as assessed by 45Ca kinetics in the intact rat.
Topics: Animals; Bone Resorption; Calcium; Calcium Radioisotopes; Diphosphonates; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Ibandronic Acid; Kinetics; Rats; Rats, Wistar; Spectrophotometry, Atomic | 1996 |
Bisphosphonates induce apoptosis in mouse macrophage-like cells in vitro by a nitric oxide-independent mechanism.
Topics: Alendronate; Animals; Apoptosis; Bone Marrow; Bone Marrow Cells; Bone Resorption; Cell Division; Cell Nucleus; Cells, Cultured; Diphosphonates; DNA; DNA Fragmentation; Electrophoresis, Polyacrylamide Gel; Ibandronic Acid; Macrophages; Mice; Necrosis; Nitric Oxide; Pamidronate; Protein Biosynthesis | 1996 |
1-Hydroxy-3-(methylpentylamino)-propylidene-1,1-bisphosphonic acid as a potent inhibitor of squalene synthase.
Topics: Animals; Bone Resorption; Caprylates; Cell Line; Cell-Free System; Cholesterol; Diphosphonates; Farnesyl-Diphosphate Farnesyltransferase; Ibandronic Acid; Lanosterol; Mevalonic Acid; Mice; Microsomes, Liver; Rats | 1996 |
[Bisphosphonates in radiotherapy].
Topics: Bone Neoplasms; Bone Resorption; Breast Neoplasms; Diphosphonates; Female; Humans; Ibandronic Acid; Radiotherapy | 1997 |
Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2.
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Cell Survival; Diphosphonates; Female; Genetic Therapy; Heart Ventricles; Humans; Ibandronic Acid; Mice; Mice, Nude; Neoplasm Invasiveness; Osteolysis; Protein Biosynthesis; Tibia; Tissue Inhibitor of Metalloproteinase-2; Transfection; Transplantation, Heterologous; Tumor Cells, Cultured | 1997 |
Research on bone metastases quickens its pace.
Topics: Bone Neoplasms; Bone Resorption; Breast Neoplasms; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Neoplasm Proteins; Palliative Care; Parathyroid Hormone-Related Protein; Proteins; Zoledronic Acid | 1997 |
Individual and combined effects of calciotropic hormones and growth factors on mineral metabolism in embryonic chick tibiae.
Topics: Alkaline Phosphatase; Animals; Bone Resorption; Calcifediol; Calcitonin; Calcitriol; Calcium; Chick Embryo; Diphosphonates; Growth Substances; Ibandronic Acid; Insulin-Like Growth Factor I; Organ Culture Techniques; Parathyroid Hormone; Tibia | 1997 |
Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras.
Topics: Alendronate; Animals; Apoptosis; Bone Resorption; Cells, Cultured; Clodronic Acid; Diphosphonates; Enzyme Inhibitors; Etidronic Acid; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA-Reductases, NADP-dependent; Ibandronic Acid; Lovastatin; Macrophages; Mevalonic Acid; Mice; Osteoclasts; Protein Prenylation; Protein Processing, Post-Translational; ras Proteins; Risedronic Acid; Structure-Activity Relationship | 1998 |
Ibandronate reduces osteolytic lesions but not tumor burden in a murine model of myeloma bone disease.
Topics: Animals; Bone Neoplasms; Bone Resorption; Diphosphonates; Humans; Ibandronic Acid; Mice; Mice, Inbred C57BL; Multiple Myeloma; Neoplasms, Experimental | 1999 |
Nitrogen-containing bisphosphonates inhibit isopentenyl pyrophosphate isomerase/farnesyl pyrophosphate synthase activity with relative potencies corresponding to their antiresorptive potencies in vitro and in vivo.
Topics: Animals; Bone Resorption; Brain; Carbon-Carbon Double Bond Isomerases; Cattle; Clodronic Acid; Dimethylallyltranstransferase; Diphosphonates; Dose-Response Relationship, Drug; Enzyme Activation; Enzyme Inhibitors; Hemiterpenes; Ibandronic Acid; Mice; Multienzyme Complexes; Nitrogen; Pamidronate | 1999 |
The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro: A clue to the mechanism of action of nitrogen-containing bisphosphonates.
Topics: Animals; Bone and Bones; Bone Resorption; Culture Techniques; Diphosphonates; Dose-Response Relationship, Drug; Female; Ibandronic Acid; Lovastatin; Mevalonic Acid; Mice; Models, Chemical; Nitrogen; Pregnancy; Protein Prenylation | 1999 |
Intermittent and continuous administration of the bisphosphonate ibandronate in ovariohysterectomized beagle dogs: effects on bone morphometry and mineral properties.
Topics: Animals; Bone Density; Bone Resorption; Crystallization; Diphosphonates; Dogs; Drug Administration Schedule; Female; Hysterectomy; Ibandronic Acid; Ovariectomy; Ovary; Uterus | 1999 |
Treatment with ibandronate preserves bone in experimental tumour-induced bone loss.
Topics: Animals; Bone Resorption; Carcinoma 256, Walker; Diphosphonates; Ibandronic Acid; Rats; Rats, Sprague-Dawley | 2000 |
Short-term administration of the bisphosphonate ibandronate increases bone volume and prevents hyperparathyroid bone changes in mild experimental renal failure.
Topics: Alkaline Phosphatase; Animals; Bone and Bones; Bone Resorption; Calcium; Chronic Kidney Disease-Mineral and Bone Disorder; Creatinine; Diphosphonates; Female; Hyperparathyroidism, Secondary; Ibandronic Acid; Kidney Failure, Chronic; Osteocalcin; Parathyroid Hormone; Phosphorus; Rats; Rats, Sprague-Dawley | 2000 |
In vivo effects of bisphosphonates on the osteoclast mevalonate pathway.
Topics: Alendronate; Alkyl and Aryl Transferases; Animals; Bone Resorption; Diphosphonates; Enzyme Inhibitors; Etidronic Acid; Geranyltranstransferase; Hydroxymethylglutaryl CoA Reductases; Ibandronic Acid; Male; Mevalonic Acid; Osteoclasts; Rats; Rats, Sprague-Dawley; Risedronic Acid | 2000 |
Bisphosphonates alendronate and ibandronate inhibit artery calcification at doses comparable to those that inhibit bone resorption.
Topics: Alendronate; Animals; Aortic Diseases; Bone Resorption; Calcification, Physiologic; Calcinosis; Diphosphonates; Drug Administration Schedule; Etidronic Acid; Female; Humans; Ibandronic Acid; Male; Muscle, Smooth, Vascular; Osteoporosis; Rats; Rats, Sprague-Dawley; Vitamin D; Warfarin | 2001 |
Inhibition of bone resorption by the bisphosphonate BM 21.0955 is not associated with an alteration of the renal handling of calcium in rats infused with parathyroid hormone-related protein.
Topics: Absorption; Animals; Bone Resorption; Calcium; Diphosphonates; Ibandronic Acid; Kidney; Male; Parathyroid Hormone; Parathyroid Hormone-Related Protein; Proteins; Rats; Rats, Wistar | 1992 |
BM 21.0955, a potent new bisphosphonate to inhibit bone resorption.
Topics: Alendronate; Animals; Benzoates; Bone Resorption; Calcium; Clodronic Acid; Diphosphonates; Etidronic Acid; Ibandronic Acid; Injections, Intravenous; Osteoclasts; Pamidronate; Rats; Retinoids; Risedronic Acid; Spectrophotometry, Atomic; Tetracycline; Thyroxine | 1991 |